Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Support

This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

Community Practice Connections™: The Latest Advances on MET Inhibitors for Treatment of Advanced NSCLC Along Lines of Care

Release Date: April 27, 2021
Expiration Date: April 27, 2022

Activity Overview

Molecular testing is critical in the treatment of patients with NSCLC. The detection of common mutations in lung cancer genes, such as EGFR, ALK, and KRAS, has led to significant improvements in survival. Further advancements in molecular testing technology in recent years have allowed for the detection of additional biomarkers and targeted therapy in patients with NSCLC, including those with mesenchymal-epithelial transition (MET) mutations.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the Oncology Best Practice™: The Latest Advances on MET Inhibitors for Treatment of Advanced NSCLC Along Lines of Care, a series of interactive meetings hosted by leading cancer centers, large oncology practice groups, and community hospitals throughout the United States. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with NSCLC, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting, and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward a global audience of medical oncologists, pulmonologists, thoracic surgeons, and pathologists, who treat and diagnose patients with NSCLC. Physician assistants, nurse practitioners, pharmacists, researchers, and other health care professionals interested in the treatment of NSCLC will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the biological role of MET alterations in untreated NSCLC and as a resistance mechanism to EGFR-targeted therapy for NSCLC.
  • Delineate tumor tissue testing and liquid biopsy strategies that should be undertaken prior to frontline treatment and in relapsed NSCLC settings to inform clinical decision-making among patients with MET alterations.
  • Evaluate clinical trial safety and efficacy data on single-agent or combination strategies with MET-targeted agents that have been evaluated for the treatment of NSCLC.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.


D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Joyce Zeff Chair in Lung Cancer Research
Director of Thoracic Oncology
University of Colorado
Aurora, CO

Disclosures: Dr D. Ross Camidge has no relevant financial relationships with ineligible companies.

Paul K. Paik, MD
Paul K. Paik, MD
Clinical Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: EMD Serono, Bicara, Boehringer Ingelheim. Consultant: EMD Serono, Xencor, GlaxoSmithKline, Bicara, Boehringer Ingelheim, Calithera, Takeda.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By